Report
Olga Smolentseva

4D PHARMA (CORPORATE, TP 360p) | Additional analysis highlights MoA of Blautix in both IBS-C and IBS-D

4D PHARMA (CORPORATE, TP 360p) | Additional analysis highlights MoA of Blautix in both IBS-C and IBS-D
Underlying
4D Pharma

4D Pharma is engaged in research and development of pharmaceutical products in live biotherapeutic areas.

Provider
Bryan Garnier
Bryan Garnier

Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.

Analysts
Olga Smolentseva

Other Reports on these Companies
Other Reports from Bryan Garnier

ResearchPool Subscriptions

Get the most out of your insights

Get in touch